CDKN2A and gonorrhea: Research (39) suggested that the CDKN2A functional inactivation caused by modifications and deep deletions predicts poor prognosis in PAC patients. Besides, CDKN2A inactivation results in the upregulation of estrogen response-related genes, which can be reversed by paclitaxel.